Precigen (PGEN) Current Deferred Revenue (2012 - 2026)
Precigen (PGEN) reported Current Deferred Revenue of $410000.0 for Q1 2026, down 82.81% year-over-year from $2.4 million in Q1 2025, and down 20.7% quarter-over-quarter from $517000.0 in Q4 2025.
Precigen (PGEN) Current Deferred Revenue (2012 - 2026) Analysis & Trends
Precigen (PGEN) has 15 years of Current Deferred Revenue data on file, last reported at $410000.0 in Q1 2026.
- Current Deferred Revenue for Q1 2026 came in at $410000.0, down 82.81% year-over-year; the trailing twelve-month figure through Mar 2026 was $410000.0 (down 82.81% YoY), and the FY2025 annual result was $517000.0, down 12.22% from the prior year.
- Current Deferred Revenue retreated to $410000.0 in Q1 2026 per PGEN's latest filing, from $517000.0 in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $25.7 million in Q1 2022 and troughed at $15000.0 in Q2 2023.
- A 5-year average of $3.6 million and a median of $517000.0 in 2025 frame the typical range for Current Deferred Revenue.
- On a YoY basis, Current Deferred Revenue climbed as much as 9208.0% in 2023 and fell as far as 99.94% in 2023.
- A 5-year view of Current Deferred Revenue shows it stood at $25000.0 in 2022, then soared by 9208.0% to $2.3 million in 2023, then tumbled by 74.69% to $589000.0 in 2024, then declined by 12.22% to $517000.0 in 2025, then dropped by 20.7% to $410000.0 in 2026.
- Business Quant data shows PGEN's Current Deferred Revenue at $410000.0 in Q1 2026, $517000.0 in Q4 2025, and $575000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - |
| 10 | Precigen | 1.32 Bn | 1.32 Bn | 20.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 410,000.00 |
| Dec 31, 2025 | 517,000.00 |
| Sep 30, 2025 | 575,000.00 |
| Jun 30, 2025 | 413,000.00 |
| Mar 31, 2025 | 2.39 Mn |
| Dec 31, 2024 | 589,000.00 |
| Sep 30, 2024 | 407,000.00 |
| Jun 30, 2024 | 378,000.00 |
| Mar 31, 2024 | 2.30 Mn |
| Dec 31, 2023 | 2.33 Mn |
| Sep 30, 2023 | 509,000.00 |
| Jun 30, 2023 | 15,000.00 |
| Mar 31, 2023 | 1.83 Mn |
| Dec 31, 2022 | 25,000.00 |
| Sep 30, 2022 | 76,000.00 |
| Jun 30, 2022 | 23.19 Mn |
| Mar 31, 2022 | 25.69 Mn |
| Dec 31, 2021 | 1.49 Mn |
| Sep 30, 2021 | 3.69 Mn |
| Jun 30, 2021 | 26.30 Mn |